Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Background: The aim of this study is to evaluate the pharmacoeconomic profile of adding enzalutamide to first-line treatment for metastatic, hormone-sensitive prostate cancer (mHSPC) from the US and Chinese payers' perspectives.Materials and Methods: A Markov model with three health states: pro...

Descripció completa

Dades bibliogràfiques
Autors principals: Peng-Fei Zhang, Dan Xie, Qiu Li
Format: Article
Idioma:English
Publicat: Frontiers Media S.A. 2021-02-01
Col·lecció:Frontiers in Public Health
Matèries:
prostate cancer
enzalutamide
cost-effectiveness
androgen deprivation therapy
first-line
Accés en línia:https://www.frontiersin.org/articles/10.3389/fpubh.2021.608375/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2021.608375/full

Ítems similars